Under the leadership of Professor Ke Xiaoyan and Director Hu Kai, the Lymphoma and Myeloma Department utilizes existing technologies, along with the GoBroad Medical Diagnostic Platform, Hematopoietic Stem Cell Transplantation Platform, and GoBroad Medical CAR-T Treatment Platform, to explore new treatment strategies for patients with refractory and relapsed diseases, aiming to enhance the cure rates for patients with difficult-to-treat and relapsed lymphoma. Based on precise diagnosis, the team integrates targeted therapy, immunotherapy, and traditional high-dose chemotherapy, including hematopoietic stem cell transplantation techniques, to develop new treatment paradigms for patients with refractory and relapsed lymphoma.